Loading...

PCI Biotech Holding

DB:4QG
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
4QG
DB
NOK1B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The last earnings update was 10 days ago. More info.


Add to Portfolio Compare Print
4QG Share Price and Events
7 Day Returns
0%
DB:4QG
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
-
DB:4QG
-10.6%
DE Biotechs
-6.2%
DE Market
4QG Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
PCI Biotech Holding (4QG) 0% 0% -2.1% - - -
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • No trading data on 4QG.
  • No trading data on 4QG.
Price Volatility
4QG
Industry
5yr Volatility vs Market

4QG Value

 Is PCI Biotech Holding undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for PCI Biotech Holding. This is due to cash flow or dividend data being unavailable. The share price is €2.74.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for PCI Biotech Holding's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are PCI Biotech Holding's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:4QG PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in NOK NOK-1.25
OB:PCIB Share Price ** OB (2019-01-23) in NOK NOK28.4
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of PCI Biotech Holding.

DB:4QG PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OB:PCIB Share Price ÷ EPS (both in NOK)

= 28.4 ÷ -1.25

-22.7x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PCI Biotech Holding is loss making, we can't compare its value to the Europe Biotechs industry average.
  • PCI Biotech Holding is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does PCI Biotech Holding's expected growth come at a high price?
Raw Data
DB:4QG PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -22.7x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for PCI Biotech Holding, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on PCI Biotech Holding's assets?
Raw Data
DB:4QG PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in NOK NOK9.15
OB:PCIB Share Price * OB (2019-01-23) in NOK NOK28.4
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:4QG PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OB:PCIB Share Price ÷ Book Value per Share (both in NOK)

= 28.4 ÷ 9.15

3.1x

* Primary Listing of PCI Biotech Holding.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PCI Biotech Holding is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess PCI Biotech Holding's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. PCI Biotech Holding has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

4QG Future Performance

 How is PCI Biotech Holding expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PCI Biotech Holding has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.5%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is PCI Biotech Holding expected to grow at an attractive rate?
  • Unable to compare PCI Biotech Holding's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare PCI Biotech Holding's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare PCI Biotech Holding's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:4QG Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:4QG Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in NOK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:4QG Past Financials Data
Date (Data in NOK Millions) Revenue Cash Flow Net Income *
2018-12-31 10 -31 -35
2018-09-30 10 -34 -46
2018-06-30 10 -35 -48
2018-03-31 10 -34 -48
2017-12-31 10 -31 -43
2017-09-30 10 -34 -34
2017-06-30 10 -36 -33
2017-03-31 10 -35 -35
2016-12-31 10 -36 -32
2016-09-30 11 -34 -34
2016-06-30 11 -33 -34
2016-03-31 10 -34 -31

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if PCI Biotech Holding is high growth as no earnings estimate data is available.
  • Unable to determine if PCI Biotech Holding is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:4QG Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from PCI Biotech Holding Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:4QG Past Financials Data
Date (Data in NOK Millions) EPS *
2018-12-31 -1.25
2018-09-30 -1.84
2018-06-30 -1.92
2018-03-31 -1.91
2017-12-31 -1.76
2017-09-30 -1.54
2017-06-30 -1.68
2017-03-31 -2.06
2016-12-31 -2.16
2016-09-30 -2.28
2016-06-30 -2.28
2016-03-31 -2.11

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if PCI Biotech Holding will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine PCI Biotech Holding's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. PCI Biotech Holding's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. PCI Biotech Holding's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess PCI Biotech Holding's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
PCI Biotech Holding has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

4QG Past Performance

  How has PCI Biotech Holding performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare PCI Biotech Holding's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • PCI Biotech Holding does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare PCI Biotech Holding's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare PCI Biotech Holding's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
PCI Biotech Holding's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from PCI Biotech Holding Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:4QG Past Revenue, Cash Flow and Net Income Data
Date (Data in NOK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 9.59 -34.78 13.77 40.34
2018-09-30 9.68 -45.89 12.94 42.91
2018-06-30 9.79 -47.83 14.05 43.97
2018-03-31 10.06 -47.75 13.36 44.95
2017-12-31 10.25 -42.84 12.69 40.99
2017-09-30 10.41 -33.54 9.96 34.86
2017-06-30 10.39 -32.54 7.79 36.10
2017-03-31 10.32 -34.68 6.32 39.57
2016-12-31 10.48 -32.18 4.29 39.22
2016-09-30 10.57 -33.96 4.31 40.93
2016-06-30 10.66 -33.98 4.23 40.97
2016-03-31 10.44 -31.40 4.24 38.42
2015-12-31 10.47 -31.92 4.25 38.84
2015-09-30 8.69 -33.75 4.56 38.48
2015-06-30 8.12 -32.71 3.93 37.54
2015-03-31 7.94 -34.25 3.89 38.82
2014-12-31 7.30 -35.84 4.43 39.34
2014-09-30 7.74 -34.53 3.59 39.72
2014-06-30 7.51 -32.75 3.72 37.78
2014-03-31 7.26 -30.03 3.97 34.78
2013-12-31 6.68 -27.61 3.22 32.79
2013-09-30 6.08 -27.08 0.74 31.25
2013-06-30 6.02 -28.22 0.90 32.29
2013-03-31 6.23 -26.56 0.12 31.66
2012-12-31 6.75 -25.26 31.26
2012-09-30 6.98 -20.91 -0.48 29.78
2012-06-30 7.63 -15.53 -0.33 25.23

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if PCI Biotech Holding has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if PCI Biotech Holding has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if PCI Biotech Holding improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess PCI Biotech Holding's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
PCI Biotech Holding has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

4QG Health

 How is PCI Biotech Holding's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up PCI Biotech Holding's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • PCI Biotech Holding is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • PCI Biotech Holding's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of PCI Biotech Holding's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • PCI Biotech Holding has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from PCI Biotech Holding Company Filings, last reported 3 months ago.

DB:4QG Past Debt and Equity Data
Date (Data in NOK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 339.95 0.00 349.33
2018-09-30 14.91 0.00 20.54
2018-06-30 22.43 0.00 28.41
2018-03-31 28.56 0.00 38.59
2017-12-31 41.84 0.00 50.79
2017-09-30 55.94 0.00 53.76
2017-06-30 62.98 0.00 60.70
2017-03-31 68.95 0.00 69.93
2016-12-31 13.09 0.00 14.00
2016-09-30 19.62 0.00 20.66
2016-06-30 28.69 0.00 31.03
2016-03-31 37.51 0.00 39.64
2015-12-31 44.28 0.00 49.25
2015-09-30 52.34 0.00 53.90
2015-06-30 61.33 0.00 63.32
2015-03-31 66.83 0.00 71.84
2014-12-31 9.11 0.00 15.75
2014-09-30 19.02 0.00 19.65
2014-06-30 26.94 0.00 29.19
2014-03-31 34.72 0.00 38.43
2013-12-31 43.40 0.00 46.60
2013-09-30 51.86 0.00 52.53
2013-06-30 58.45 0.00 59.61
2013-03-31 63.32 0.00 66.34
2012-12-31 69.71 0.00 72.62
2012-09-30 76.86 0.00 77.98
2012-06-30 84.03 0.00 85.90
  • PCI Biotech Holding has no debt.
  • PCI Biotech Holding has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • PCI Biotech Holding has sufficient cash runway for more than 3 years based on current free cash flow.
  • PCI Biotech Holding has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -1.1% each year.
X
Financial health checks
We assess PCI Biotech Holding's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. PCI Biotech Holding has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

4QG Dividends

 What is PCI Biotech Holding's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from PCI Biotech Holding dividends.
If you bought €2,000 of PCI Biotech Holding shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate PCI Biotech Holding's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate PCI Biotech Holding's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:4QG Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as PCI Biotech Holding has not reported any payouts.
  • Unable to verify if PCI Biotech Holding's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of PCI Biotech Holding's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as PCI Biotech Holding has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess PCI Biotech Holding's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can PCI Biotech Holding afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. PCI Biotech Holding has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

4QG Management

 What is the CEO of PCI Biotech Holding's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Per Walday
COMPENSATION NOK2,137,000
AGE 58
TENURE AS CEO 11 years
CEO Bio

Dr. Per Walday, Ph.D., has been the Chief Executive Officer at PCI Biotech AS since 2008. Dr. Walday has been the Chief Executive Officer at PCI Biotech Holding ASA since April 2008 and served as its Managing Director. He served as the Chief Executive Officer of PCI Biotech at PhotoCure ASA since April 2008. Dr. Walday served as the Global Head of Project Management of GE Healthcare with responsibility for project management of all pharmaceutical product development. Dr. Walday served as Manager positions in Nycomed Imaging/Amersham Health developing mainstream diagnostic drugs found in the market today. He has a broad international network and is experienced with business development and approvals of new products in the international scene of the pharmaceutical industry. Dr. Walday holds a Ph. D. in Physiology from the University of Oslo.

CEO Compensation
  • Per's compensation has increased whilst company is loss making.
  • Per's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the PCI Biotech Holding management team in years:

5.5
Average Tenure
58
Average Age
  • The average tenure for the PCI Biotech Holding management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Per Walday

TITLE
Chief Executive Officer
COMPENSATION
NOK2M
AGE
58
TENURE
11 yrs

Ronny Skuggedal

TITLE
Chief Financial Officer
COMPENSATION
NOK1M
AGE
42
TENURE
5.5 yrs

Anders Høgset

TITLE
Chief Scientific Officer
COMPENSATION
NOK1M
AGE
64
TENURE
11.3 yrs

Kristin Eivindvik

TITLE
Chief Development Officer
COMPENSATION
NOK1M
AGE
57
TENURE
0.2 yrs

Hans Olivecrona

TITLE
Chief Medical Officer
COMPENSATION
NOK949K
AGE
60
TENURE
1.7 yrs
Board of Directors Tenure

Average tenure and age of the PCI Biotech Holding board of directors in years:

2.9
Average Tenure
57
Average Age
  • The average tenure for the PCI Biotech Holding board of directors is less than 3 years, this suggests a new board.
Board of Directors

Hans Bøhn

TITLE
Chairman
COMPENSATION
NOK275K
AGE
63
TENURE
2.9 yrs

Hilde Steineger

TITLE
Director
COMPENSATION
NOK171K
AGE
52
TENURE
4.9 yrs

Christina Herder

TITLE
Director
COMPENSATION
NOK171K
AGE
57
TENURE
3.9 yrs

Lars Viksmoen

TITLE
Director
COMPENSATION
NOK171K
AGE
69
TENURE
2.9 yrs

Andrew Hughes

TITLE
Director
AGE
54
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
06. Jun 18 Sell The Norwegian Radium Hospital Research Foundation Company 31. May 18 31. May 18 -65,500 €5.56 €-363,897
X
Management checks
We assess PCI Biotech Holding's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. PCI Biotech Holding has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

4QG News

Simply Wall St News

4QG Company Info

Description

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. Its PCI technology induces light-triggered endosomal release, which enhances various therapeutic modalities, such as small molecules, vaccines, and nucleic acids. The company’s lead product candidate is Amphinex, a photosensitiser fimaporfin. Its PCI technology is applied to three distinct anticancer paradigms, including fimaCHEM, a Phase I/II clinical study in bile duct cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination; and fimaNAc, a nucleic acid therapeutics delivery technology. The company has research collaboration agreements with RXi Pharmaceuticals; Ultimovacs AS; BioNTech AG; eTheRNA immunotherapies NV; and Bavarian Nordic A/S. PCI Biotech Holding ASA was founded in 2000 and is headquartered in Oslo, Norway.

Details
Name: PCI Biotech Holding ASA
4QG
Exchange: DB
Founded: 2000
NOK110,490,825
37,225,890
Website: http://www.pcibiotech.com
Address: PCI Biotech Holding ASA
Ullernchausséen 64,
Oslo,
Oslo, 0379,
Norway
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OB PCIB Ordinary Shares Oslo Bors NO NOK 20. Jun 2008
DB 4QG Ordinary Shares Deutsche Boerse AG DE EUR 20. Jun 2008
LSE 0JGL Ordinary Shares London Stock Exchange GB NOK 20. Jun 2008
Number of employees
Current staff
Staff numbers
11
PCI Biotech Holding employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 21:15
End of day share price update: 2019/01/23 00:00
Last earnings filing: 2019/04/09
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.